News & Updates

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Elevated nonhigh-density lipoprotein cholesterol (non–HDL-C) levels in childhood that persist into adulthood poses an increased risk of cardiovascular disease (CVD), according to a study. But the good news is that the resolution of dyslipidaemic non–HDL-C levels adulthood may help prevent CVD events.

A second pre-eclampsia does not lead to worse outcomes relative to the first occurrence, suggests a study. On the contrary, some clinical features and effects appear to be better in the second event.

Individuals with inflammatory bowel disease (IBD) appear to be at increased risk of acute coronary syndrome (ACS) compared with those from the general population, according to a Swedish nationwide cohort study.

Patients with atrial fibrillation (AF) who take oral anticoagulants (OACs) and selective serotonin reuptake inhibitors (SSRIs) at the same time appear to have a higher likelihood of major bleeding.

 Exposure to second-hand tobacco smoke may increase the risk of developing atrial fibrillation (AF), as shown in a population-based cohort study using the UK Biobank database.

In the CRESCENT trial, a mandibular advancement device (MAD) was noninferior to a continuous positive airway pressure (CPAP) machine for reducing 24-hr mean arterial blood pressure (MBP) in individuals with obstructive sleep apnoea (OSA), uncontrolled hypertension, and high cardiovascular (CV) risk.